NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $201.28 +1.54 (+0.77%) As of 12:27 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsBuy This Stock About iShares Biotechnology ETF (NASDAQ:IBB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBB alerts:Sign Up Key Stats Today's Range$198.07▼$201.5650-Day Range$165.93▼$200.0252-Week Range$134.50▼$201.56Volume796,142 shsAverage Volume1.65 million shsMarket Capitalization$9.94 billionAssets Under Management$9.91 billionDividend Yield0.20%Net Expense Ratio0.44%Aggregate RatingModerate Buy ETF Overview iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc. Read More iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.44%0.55%0.57%0.54%0.53%Other Expenses0.00%0.52%0.53%0.39%0.54%Total Expense0.44%0.76%0.75%0.69%0.73%Fee Waiver0.00%-0.85%-0.67%-0.41%-0.68%Net Expense0.44%0.58%0.63%0.61%0.60% Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBB ETF News HeadlinesThese New Drugs Could Fuel Fresh Highs for Biotech and Pharma StocksAugust 7, 2026 | barrons.comSector Update: Healthcare Stocks Decline Monday AfternoonAugust 3, 2026 | finance.yahoo.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.August 12 at 1:00 AM | Porter & Company (Ad)FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove ItJuly 27, 2026 | 247wallst.comHealthcare Systems' Liquidity ChallengeJuly 25, 2026 | seekingalpha.comiShares Trust - iShares Biotechnology ETFJuly 23, 2026 | money.usnews.comSee More Headlines IBB ETF - Frequently Asked Questions How have IBB shares performed this year? iShares Biotechnology ETF's stock was trading at $168.77 at the start of the year. Since then, IBB shares have increased by 19.1% and is now trading at $201.00. When did iShares Biotechnology ETF's stock split? iShares Biotechnology ETF's stock split on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were distributed to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares Biotechnology ETF's major shareholders? iShares Biotechnology ETF's top institutional shareholders include Janney Montgomery Scott LLC (1.32%), Apella Capital LLC (0.12%), HighTower Advisors LLC (0.09%) and Neville Rodie & Shaw Inc. (0.09%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings253 Fund Statistics Assets Under Management$9.91 billion Average Daily Volume$1.45 million Discount/Premium-0.06% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume992 Put Options367 Call Options625 Short Interest10,042,470 shs Miscellaneous Outstanding Shares49,400,000Beta0.70 Creation Unit50,000 Creation Fee$614.00 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report Top 10 IBB HoldingsAmgen (NASDAQ:AMGN)Holding Weight: 8.76%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 7.84%Gilead Sciences (NASDAQ:GILD)Holding Weight: 7.09%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 6.01%argenex (NASDAQ:ARGX)Holding Weight: 3.49%Natera (NASDAQ:NTRA)Holding Weight: 2.91%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 2.91%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.36%Biogen (NASDAQ:BIIB)Holding Weight: 2.34%Illumina (NASDAQ:ILMN)Holding Weight: 2.34%Full Holdings DetailsIBB Sector ExposureIBB Industry Exposure This page (NASDAQ:IBB) was last updated on 8/12/2026 by MarketBeat.com Staff. From Our PartnersMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe trading strategy that works BECAUSE you have a lifeTim Sykes built a trading strategy for people who can't watch charts from 9:30 to 4:00 every day. It's not ...Tim Sykes | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe oil crisis is spreading faster than you thinkTanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
